ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 210

Medication Adherence In Patients With Gout: A Systematic Review

Mary De Vera1,2, Sharan Rai1 and Vidula Bhole3, 1Arthritis Research Centre of Canada, Richmond, BC, Canada, 2Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 3EpiSolutions Consultancy Services, Thane, India

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Compliance, gout and quality of care

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Health Services Research, Quality Measures and Quality of Care-Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Recent data suggesting the growing problem of medication non-adherence in gout has called for the need to understand the magnitude of the problem as well as its determinants. To date, only one systematic review has summarized medication adherence across a variety rheumatic diseases, including three studies in gout. To update this data as well as better understand patterns and determinants of adherence in this population, our objective was to a conduct a systematic review of the literature examining medication adherence among patients with gout.

Methods: We conducted a systematic search of MEDLINE (1946-), EMBASE (1974-), and INTERNATIONAL PHARMACEUTICAL ABSTRACTS (1970-) databases and selected original studies that included patients with gout and measured and/or reported medication adherence in real-world settings. We extracted information on: 1) study design, 2) sample size, 3) length of follow-up, 4) data source (e.g. prescription records vs. electronic monitoring vs. self-report), and 5) adherence measures and reported estimates. We assessed quality of studies by adapting and applying published recommendations for the reporting, assessment, and evaluation of medication adherence studies.

Results: After screening 963 potential articles, 14 met inclusion criteria. We divided studies according to methods used to measure adherence including prescription records (9), electronic monitoring devices (1), and self-report (4). Studies using prescription records have the largest sample sizes and lowest reported adherence, ranging from 17% to 44%.  Higher adherence rates (or scores) were reported in studies based on self-report, which may be due to social desirability bias. With respect to determinants, younger age has been shown as a predictor of poor adherence while other factors including gender and gout-related factors (e.g., flares) are less consistent across studies.

Conclusion: This is the first systematic review of medication adherence, with particular focus on gout patients. Adherence rates may vary according to methods used to measure adherence. Overall, synthesis of current evidence suggest that medication non-adherence is substantial in gout. Findings highlight the importance of discussing adherence with gout medications during health care professional encounters with gout patients.

Study

N

Follow-up

Adherence Measure

Main Result

Prescription Records

Riedel 2004

5,597

2 yr

weighted average compliance rate

18% adherent

Sarawate 2006

2,405

2 yr

medication possession ratio >0.80

26% adherent

Briesacher 2008

9,715

1 yr

medication possession ratio >0.80

36.8% adherent

Solomon 2008

9,823

1 yr

proportion days covered >0.80

36% adherent

Halpern 2009*

10,070

1 yr

medication possession ratio >0.80

44% adherent

Harrold 2009

4,166

6 yr

medication possession ratio >0.80

44% adherent

Harrold 2010*

4,166

6 yr

therapy gap (>60 days no refill)

30% adherent (no gap)

Park 2012

352

1 yr

proportion days covered >0.80

27% adherent

Zandman 2013

7,644

6 yr

proportion days covered >0.80

17% adherent

Electronic  Monitoring

de Klerk 2003

29

1 yr

taking compliance

dosing compliance

colchicine:  65%

allopurinol: 84%

colchicine:  44%

allopurinol: 74%

Self-Report

Silva 2010

34

1 yr

taking medication regularly

16.7% adherent

Dalbeth 2011*

142

n/a

questionnaire score (45=high)

39.8

Dalbeth 2012*

273

n/a

questionnaire score (45=high)

40.2

Martini 2012*

60

n/a

semi-structured interview

79% adherent

*medication adherence evaluated as exposure and not outcome


Disclosure:

M. De Vera,
None;

S. Rai,
None;

V. Bhole,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/medication-adherence-in-patients-with-gout-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology